HALO FY 2020 Earnings Report — Halozyme Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

Halozyme Therapeutics, Inc.HALO

FY 2020 Earnings

Reported February 23, 2021

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2020	Prior Q	FY 2019	QoQ Change	YoY Change
Revenue	$268M	—	$196M	—	36.5%
Op. Income	$144M	—	-$68M	—	313.4%
Gross Margin	83.8%	—	76.8%	—	7.0pp
Net Margin	48.2%	—	-36.9%	—	85.1pp
EPS (Diluted)	$0.91	—	$-0.50	—	282.0%
Free Cash Flow	$53M	—	-$89M	—	159.2%

Revenue Flow

Item	Amount
REVENUE	$268M
Cost of Revenue	$43M
GROSS PROFIT	$224M
R&D Expenses	$34M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$46M
Other Expenses	$0
Operating Expenses	$80M
Cost & Expenses	$123M
OPERATING INCOME	$144M
Interest Income	$0
Interest Expense	$20M
Other Income/Expenses	-$15M
INCOME BEFORE TAX	$129M
Income Tax Expense	$217.0K
Net Income from Continuing Ops	$129M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$129M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$129M
D&A	$3M
EBIT	$150M
EBITDA	$153M
EPS	$1
EPS Diluted	$1

Income Statement

Item	Amount
REVENUE	$268M
Cost of Revenue	$43M
GROSS PROFIT	$224M
R&D Expenses	$34M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$46M
Other Expenses	$0
Operating Expenses	$80M
Cost & Expenses	$123M
OPERATING INCOME	$144M
Interest Income	$0
Interest Expense	$20M
Other Income/Expenses	-$15M
INCOME BEFORE TAX	$129M
Income Tax Expense	$217.0K
Net Income from Continuing Ops	$129M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$129M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$129M
D&A	$3M
EBIT	$150M
EBITDA	$153M
EPS	$1
EPS Diluted	$1

Cash Flow Statement

Item	Amount
Net Income	$129M
Depreciation & Amortization	$17M
Stock-Based Compensation	$17M
Deferred Income Tax	$0
Other Non-Cash Items	-$41M
Change in Working Capital	-$67M
OPERATING CASH FLOW	$55M
Capital Expenditure	-$3M
Acquisitions (Net)	$0
Purchases of Investments	$0
Sales/Maturities of Investments	$0
Other Investing Activities	$81M
NET CASH FROM INVESTING	$78M
Net Debt Issuance	-$20M
Common Stock Repurchased	-$150M
Common Dividends Paid	$0
Other Financing Activities	$63M
NET CASH FROM FINANCING	-$106M
FREE CASH FLOW	$53M
Net Change in Cash	$28M

Balance Sheet

Item	Amount
Cash & Equivalents	$148M
Short-Term Investments	$220M
Net Receivables	$98M
Inventory	$61M
Other Current Assets	$0
TOTAL CURRENT ASSETS	$555M
PP&E (Net)	$11M
Goodwill	$0
Intangible Assets	$0
Long-Term Investments	$0
Tax Assets	$0
Other Non-Current Assets	$15M
TOTAL NON-CURRENT ASSETS	$25M
TOTAL ASSETS	$580M
Account Payables	$2M
Short-Term Debt	$397M
Deferred Revenue	$2M
Other Current Liabilities	$0
TOTAL CURRENT LIABILITIES	$421M
Long-Term Debt	$0
Deferred Revenue NC	$4M
Deferred Tax Liabilities	$0
Other Non-Current Liabilities	$3M
TOTAL NON-CURRENT LIABILITIES	$7M
TOTAL LIABILITIES	$429M
Common Stock	$135.0K
Additional Paid-In Capital	$625M
Retained Earnings	-$475M
Treasury Stock	$0
Accum. Other Comp. Income	$22.0K
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$151M
Minority Interest	$0
TOTAL EQUITY	$151M
TOTAL LIABILITIES & EQUITY	$580M
Total Debt	$397M
Net Debt	$250M